---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-110821"
form_type: "8-K"
ticker: "PLX"
cik: "0001006281"
company_name: "Protalix BioTherapeutics, Inc."
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:05:46.214371+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Protalix Q3 revenue flat at $17.9M; net income down to $2.4M; PRX-115 phase 2 IND effective

## Summary
- Q3 2025 revenue flat at $17.9M; net income $2.4M ($0.03 EPS) vs $3.2M ($0.04) in Q3 2024.
- Nine-month 2025 revenue $43.6M (+24% YoY); net loss improved to $1.1M from $3.6M.
- PRX-115 IND effective; phase 2 trial for uncontrolled gout planned for late 2025.
- Chiesi requested re-examination of CHMP negative opinion on Elfabrio 2 mg/kg E4W; 1 mg/kg E2W still approved.
- Cash and equivalents $29.4M at Sep 30, 2025; sufficient for at least 12 months.

## SEC filing metadata
- accession: 0001104659-25-110821
- form_type: 8-K
- ticker: PLX
- cik: 0001006281
- company_name: Protalix BioTherapeutics, Inc.
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1006281/000110465925110821/0001104659-25-110821-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1006281/000110465925110821/plx-20251113x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-110821
- JSON: https://secwatch.observer/filing/0001104659-25-110821.json
- Plain text: https://secwatch.observer/filing/0001104659-25-110821.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.